Literature DB >> 89558

Clonidine in Tourette's syndrome.

D J Cohen, J G Young, J A Nathanson, B A Shaywitz.   

Abstract

Tourette's syndrome (TS) is a neuropsychiatric disorder characterised by changing motor and phonic tics, compulsive actions, and other behavioural symptoms. Small doses of clonidine, an alpha-adrenergic agonist, improves the condition in some children unresponsive to haloperidol. Clonidine presumably acts by inhibiting central noradrenergic function. Metabolic and clinical findings suggest the involvement of monoamines, including noradrenaline, dopamine, and serotonin, in TS.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 89558     DOI: 10.1016/s0140-6736(79)91614-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  23 in total

Review 1.  The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder.

Authors:  Amy F T Arnsten
Journal:  Expert Rev Neurother       Date:  2010-10       Impact factor: 4.618

Review 2.  Neurobiological substrates of Tourette's disorder.

Authors:  James F Leckman; Michael H Bloch; Megan E Smith; Daouia Larabi; Michelle Hampson
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-08       Impact factor: 2.576

3.  Duloxetine may improve some symptoms of attention-deficit/hyperactivity disorder.

Authors:  Helmut Niederhofer
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

4.  The D1CT-7 mouse model of Tourette syndrome displays sensorimotor gating deficits in response to spatial confinement.

Authors:  Sean C Godar; Laura J Mosher; Hunter J Strathman; Andrea M Gochi; Cori M Jones; Stephen C Fowler; Marco Bortolato
Journal:  Br J Pharmacol       Date:  2015-08-10       Impact factor: 8.739

Review 5.  Mouse models of neurodevelopmental disease of the basal ganglia and associated circuits.

Authors:  Samuel S Pappas; Daniel K Leventhal; Roger L Albin; William T Dauer
Journal:  Curr Top Dev Biol       Date:  2014       Impact factor: 4.897

Review 6.  Gilles de la Tourette syndrome: a review.

Authors:  M Lawden
Journal:  J R Soc Med       Date:  1986-05       Impact factor: 5.344

Review 7.  Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Authors:  Jose Martinez-Raga; Carlos Knecht; Nestor Szerman; María I Martinez
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

8.  Catecholamine metabolism during clonidine withdrawal.

Authors:  P R Martin; M H Ebert; E K Gordon; H Weingartner; I J Kopin
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 9.  Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness.

Authors:  Lawrence Scahill
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder.

Authors:  Jonathan T Ting; Guoping Feng
Journal:  Curr Chem Genomics       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.